Illumina, Inc. ILMN · SEC Filings

8.6K

Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily thro...

Price220.78

Market Cap33.38 B

Float150.68 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 31, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 1, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 31, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 1, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Illumina Reports Third Quarter 2026 Financial Results and Raises Full Year Guidance

Oct 29, 2026

8-K

Illumina, Inc. Establishes $1.0 Billion Unsecured Commercial Paper Program

Oct 13, 2026

8-K

Illumina, Inc. Completes $300 Million Public Offering of 4.950% Notes Due 2029

Aug 17, 2026

8-K

Illumina, Inc. Enters Into New $1,000 Million Revolving Credit Facility

Aug 13, 2026

8-K

Illumina, Inc. Announces Pricing of $300 Million Senior Notes Offering

Aug 12, 2026

8-K

Illumina Reaches Settlement Agreement in GRAIL-Related Litigation

Aug 7, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B2

Form 424B2 - Prospectus [Rule 424(b)(2)]

Aug 12, 2026

424B2

Form 424B2 - Prospectus [Rule 424(b)(2)]

Aug 10, 2026

424B2

Form 424B2 - Prospectus [Rule 424(b)(2)]

Nov 12, 2025

424B2

Form 424B2 - Prospectus [Rule 424(b)(2)]

Nov 10, 2025

424B2

Form 424B2 - Prospectus [Rule 424(b)(2)]

Sep 5, 2024

424B2

Form 424B2 - Prospectus [Rule 424(b)(2)]

Sep 4, 2024

Registrations

TYPE

HEADLINE

FILED AT

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Aug 10, 2026

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Nov 10, 2025

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Sep 4, 2024

S-3ASR

SHELF

Sep 4, 2024

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 1, 2023

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Nov 29, 2022

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 9, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 9, 2026

DEFR14A

Form DEFR14A - Revised definitive proxy soliciting materials

Apr 16, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 9, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 9, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 4, 2024

Ownerships

TYPE

HEADLINE

FILED AT

4

NEWBarnard Steven (Reporting)

Nov 9, 2026

4

NEWEricksen Scott D (Reporting)

Nov 9, 2026

4

NEWLeckman Patricia (Reporting)

Nov 9, 2026

4

NEWPegels Kevin Carl (Reporting)

Nov 9, 2026

4

Meister Keith A. (Reporting)

Nov 5, 2026

144

Form 144 - Report of proposed sale of securities

Nov 3, 2026

Other

TYPE

HEADLINE

FILED AT

SD

Form SD - Specialized disclosure report

May 19, 2026

SD

Form SD - Specialized disclosure report

May 16, 2025

SD

Form SD - Specialized disclosure report

May 20, 2024

SD

Form SD - Specialized disclosure report

May 31, 2023

LETTER

Form UPLOAD - SEC-generated letter

Apr 17, 2023

CORRESP

Form CORRESP - Correspondence

Apr 7, 2023